CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
CD47 Antigen
/ metabolism
Cell Line, Tumor
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Germinal Center
/ immunology
Humans
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Macrophages
/ immunology
Middle Aged
Phagocytosis
Prednisone
/ administration & dosage
Prognosis
Rituximab
/ administration & dosage
Vincristine
/ administration & dosage
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
31
10
2018
revised:
27
02
2019
accepted:
09
08
2019
pubmed:
15
8
2019
medline:
25
9
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Addition of rituximab (R) to "CHOP" (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to disease due to intrinsic resistance or relapse. A potential negative regulator of DLBCL treatment outcome is the CD47 "don't eat me" immune checkpoint. To delineate the impact of CD47, we used a clinically and molecularly well-annotated cohort of 939 DLBCL patients, comprising both germinal center B-cell (GCB) and non-GCB DLBCL subtypes, treated with either CHOP or R-CHOP. High (above median)
Identifiants
pubmed: 31409608
pii: 2326-6066.CIR-18-0781
doi: 10.1158/2326-6066.CIR-18-0781
doi:
Substances chimiques
CD47 Antigen
0
CD47 protein, human
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1663-1671Informations de copyright
©2019 American Association for Cancer Research.